LifeWatch AG: LifeWatch AG and BioTelemetry, Inc. Announce Receipt of Antitrust Clearance Montag, 08. Mai 2017 - 16:22

LifeWatch AG / Key word(s): Offer
LifeWatch AG: LifeWatch AG and BioTelemetry, Inc. Announce Receipt of
Antitrust Clearance

08-May-2017 / 15:22 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR

---------------------------------------------------------------------------

LifeWatch AG and BioTelemetry, Inc. Announce Receipt of Antitrust Clearance

Zug/Switzerland and Malvern, PA - May 8, 2017 - LifeWatch AG (SIX Swiss
Exchange: LIFE) and BioTelemetry, Inc. (NASDAQ:BEAT) announce today that,
effective on May 5, 2017, they received early termination of the applicable
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 ("HSR") with respect to its previously announced tender offer by
BioTelemetry to acquire all of the capital stock of LifeWatch AG. This
clearance comes without any condition on or undertaking by LifeWatch,
BioTelemetry or any of their respective subsidiaries. LifeWatch and
BioTelemetry also received all necessary antitrust approvals from the
Macedonian Commission, the need for which was due to the operations of
LifeWatch Macedonia, a wholly owned subsidiary of LifeWatch AG.

The expiration of the HSR waiting period satisfies one of the closing
conditions of the pending tender offer, which remains subject to other
closing conditions as described in the prospectus for the offer published by
BioTelemetry on April 24, 2017. Subject to the satisfaction of the other
conditions, BioTelemetry expects the transaction to close in the third
quarter of 2017.

According to the current timetable, the main offer period starts on May 10,
2017 and is expected to end on May 23, 2017, subject to any extension of the
offer period.

For further questions:
LifeWatch AG, Andrew Moore, CFO
c/o Communicators AG , Ralph Spillmann
Mobile: +41 79 514 64 84
E-Mail: investor-relations@lifewatch.com

About LifeWatch AG
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),
Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote
diagnostic patient monitoring services. LifeWatch's services provide
physicians with critical information to determine appropriate treatment and
thereby improve patient outcomes. LifeWatch AG has operative subsidiaries in
the United States, in Switzerland, Israel and Turkey, and is the parent
company of LifeWatch Services Inc., LifeWatch Technologies, Ltd. and
LifeWatch Turkey Holding AG (joint venture). LifeWatch Services, Inc. is a
leading U.S.-based provider of cardiac monitoring services. LifeWatch
Technologies Ltd., based in Israel, is a leading manufacturer of digital
health products. LifeWatch Sağlık Hizmetlerine A.S. is the operative Turkish
subsidiary of LifeWatch Turkey Holding AG and provider of mobile cardiac
telemetry services in Turkey. For additional information, please visit
www.lifewatch.com.

Sign up for customized e-mail alerts and documentation requests at
https://www.lifewatch.com/Investor-Relations/Alert-Service.html

About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading
wireless medical technology company focused on the delivery of health
information to improve quality of life and reduce cost of care. The company
currently provides cardiac monitoring services, original equipment
manufacturing with a primary focus on cardiac monitoring devices and
centralized core laboratory services. More information can be found at
www.biotelinc.com.


Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements regarding, among
other things, statements about BioTelemetry's proposed acquisition of
LifeWatch AG, including the timing and success of the tender offer. These
statements may be identified by words such as "expect," "anticipate,"
"estimate," "intend," "plan," "believe," "promises", "projects," and other
words and terms of similar meaning. Such forward-looking statements are
based on current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any of these
expectations, and could cause actual outcomes and results to differ
materially from current expectations. Factors that may materially affect
such forward-looking statements include: BioTelemetry's ability to
successfully complete the tender offer for LifeWatch's shares and the
failure of any of the conditions to BioTelemetry's tender offer to be
satisfied. For further details and a discussion of these and other risks and
uncertainties, please see BioTelemetry's public filings with the Securities
and Exchange Commission, including the company's latest periodic reports on
Form 10-K and 10-Q respectively, LifeWatch's past press releases, reports
and other information posted on LifeWatch's website. Readers are cautioned
not to put undue reliance on forward-looking statements, which reflect only
opinions as of the date of this press release. BioTelemetry and LifeWatch do
not undertake, and specifically disclaim, any obligation to publicly update
or amend any forward-looking statement, whether as a result of new
information, future events, or otherwise.

OFFER RESTRICTIONS
The public tender offer described in the offer documents (the "Offer") is
not being and will not be made, directly or indirectly, in any country or
jurisdiction in which it would be considered unlawful or otherwise violate
any applicable laws or regulations, or which would require BioTelemetry or
any of its subsidiaries to change or amend the terms or conditions of the
Offer in any material way, to make an additional filing with any
governmental, regulatory or other authority or take additional action in
relation to the Offer. It is not intended to extend the Offer to any such
country or jurisdiction. Any such documents relating to the Offer must
neither be distributed in any such country or jurisdiction nor be sent into
such country or jurisdiction, and must not be used for the purpose of
soliciting the purchase of securities of LifeWatch by any person or entity
resident or incorporated in any such country or jurisdiction.

Notice to U.S. Persons Holding LifeWatch Shares
The Offer is made for the securities of a non-U.S. company. The Offer is
subject to the disclosure and procedural requirements of Switzerland, which
are different from those of the United States (the "U.S.").

The Offer may not be accepted before expiration of a cooling-off period of
ten (10) trading days, which will run from April 25, 2017 through May 9,
2017, unless extended by the Swiss Takeover Board.

According to the laws of Switzerland, LifeWatch shares tendered into the
Offer may be withdrawn after they are tendered until the expiration of the
main offer period.

BioTelemetry and any of its subsidiaries and any advisor, broker or
financial institution acting as an agent or for the account or benefit of
BioTelemetry or the Offeror may, subject to applicable Swiss securities
laws, rules and regulations, make certain purchases of, or arrangements to
purchase, LifeWatch shares from shareholders of LifeWatch who are willing to
sell their LifeWatch shares outside the Offer from time to time, including
purchases in the open market at prevailing prices or in private transactions
at negotiated prices. The Offeror will disclose promptly any information
regarding such purchases of LifeWatch shares in Switzerland through the
electronic media and/or the stock exchange and in the U.S. by means of a
press release, if and to the extent required under applicable laws, rules
and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim
arising out of U.S. federal securities laws, since LifeWatch is located in a
non-U.S. jurisdiction, and some or all of its officers and directors may be
residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a
non-U.S. company or its officers or directors in a non-U.S. court for
violations of the U.S. securities laws. Further, it may be difficult to
compel a non-U.S. company and its affiliates to subject themselves to a U.S.
court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S.
shareholder will generally be a taxable transaction for U.S. federal, state
and local income tax purposes. Each U.S. shareholder is urged to consult his
independent professional adviser immediately regarding the tax consequences
of acceptance of the Offer.

Securities may not be offered or sold in the U.S. absent registration or an
exemption from registration under the U.S. Securities Act. It is expected
that the Offer will be subject to a Tier I exemption pursuant to Rule
14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that
the issuance of BioTelemetry Common Stock in connection therewith will be
exempt from registration under the U.S. Securities Act of 1933, as amended,
pursuant to Rule 802 thereof.

Neither the Securities and Exchange Commission nor any securities commission
of any State of the U.S. has (a) approved or disapproved of the Offer, (b)
passed upon the merits or fairness of the Offer, or (c) passed upon the
adequacy or accuracy of the disclosure in the pre-announcement. Any
representation to the contrary is a criminal offense in the U.S.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------